Exclusive details on Cybin's IND application with the FDA, a move that could make its CYB003 compound the first psilocybin analog to be evaluated in Phase 1/2a development.
Subscribe to:
Post Comments (Atom)
< + > Provider Enrollment is a Data Problem Hiding in the Denial Queue
The following is a guest article by Madison Gardner, President at AMS Solutions, Inc. A claim can pass every check a practice controls and ...
No comments:
Post a Comment